IPCA LABORATORIES LTD.
NSE : IPCALABBSE : 524494ISIN
CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse
: Ipca Laboratories
BSE1921.8015.65 (+0.82 % )
PREV CLOSE (Rs.) 1906.15
OPEN PRICE (Rs.) 1907.00
BID PRICE (QTY) 1920.25 (25 )
OFFER PRICE (QTY) 1922.15 (1 )
VOLUME 2435
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1920.95 13.9 (+0.73 % )
PREV CLOSE(Rs.) 1907.05
OPEN PRICE (Rs.) 1871.00
BID PRICE (QTY) 1920.95 (28 )
OFFER PRICE (QTY) 1921.35 (52 )
VOLUME 76321
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Financial ratio
Particulars | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 47.92 | 35.27 | 18.97 | 15.42 | 7.38 |
CEPS(Rs) | 65.05 | 49.58 | 33.39 | 29.77 | 20.56 |
DPS(Rs) | 5.00 | 3.00 | 1.00 | 1.00 | 0.00 |
Book NAV/Share(Rs) | 286.15 | 247.12 | 213.02 | 194.55 | 179.02 |
Tax Rate(%) | 18.12 | 19.01 | 17.34 | 24.98 | 17.52 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 19.16 | 17.98 | 13.46 | 12.93 | 9.42 |
EBIT Margin(%) | 16.49 | 15.12 | 9.82 | 9.25 | 5.20 |
Pre Tax Margin(%) | 16.06 | 14.53 | 8.98 | 8.42 | 4.01 |
PAT Margin (%) | 13.15 | 11.77 | 7.42 | 6.31 | 3.31 |
Cash Profit Margin (%) | 17.68 | 16.60 | 12.83 | 11.70 | 8.93 |
Performance Ratios | |||||
ROA(%) | 12.47 | 10.25 | 6.03 | 5.17 | 2.50 |
ROE(%) | 18.15 | 15.28 | 9.47 | 8.60 | 4.31 |
ROCE(%) | 19.92 | 16.53 | 9.94 | 9.44 | 4.82 |
Asset Turnover(x) | 0.95 | 0.87 | 0.81 | 0.82 | 0.75 |
Sales/Fixed Asset(x) | 1.64 | 1.48 | 1.37 | 1.43 | 1.23 |
Working Capital/Sales(x) | 3.04 | 2.95 | 3.50 | 4.09 | 4.46 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.61 | 0.68 | 0.73 | 0.70 | 0.81 |
Receivable days | 61.90 | 62.09 | 61.27 | 53.75 | 50.16 |
Inventory Days | 94.05 | 94.47 | 97.98 | 97.70 | 110.76 |
Payable days | 49.85 | 51.13 | 50.35 | 52.23 | 52.92 |
Valuation Parameters | |||||
PER(x) | 28.97 | 27.86 | 34.52 | 40.44 | 78.55 |
PCE(x) | 21.34 | 19.82 | 19.61 | 20.94 | 28.20 |
Price/Book(x) | 4.85 | 3.98 | 3.07 | 3.20 | 3.24 |
Yield(%) | 0.36 | 0.31 | 0.15 | 0.16 | 0.00 |
EV/Net Sales(x) | 3.86 | 3.36 | 2.68 | 2.71 | 2.79 |
EV/Core EBITDA(x) | 18.26 | 16.73 | 17.48 | 18.18 | 25.47 |
EV/EBIT(x) | 23.27 | 22.08 | 27.12 | 28.75 | 52.96 |
EV/CE(x) | 3.39 | 2.77 | 2.12 | 2.16 | 2.06 |
M Cap / Sales | 3.80 | 3.31 | 2.54 | 2.49 | 2.55 |
Growth Ratio | |||||
Net Sales Growth(%) | 23.32 | 14.98 | 3.22 | 10.08 | -8.82 |
Core EBITDA Growth(%) | 29.76 | 50.57 | 6.36 | 49.52 | -45.10 |
EBIT Growth(%) | 34.35 | 77.00 | 8.44 | 96.58 | -61.55 |
PAT Growth(%) | 37.69 | 82.24 | 20.14 | 110.81 | -62.88 |
EPS Growth(%) | 35.88 | 85.89 | 23.07 | 108.87 | -63.36 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.13 | 0.15 | 0.23 | 0.29 | 0.38 |
Current Ratio(x) | 2.15 | 2.17 | 1.93 | 1.82 | 1.67 |
Quick Ratio(x) | 1.16 | 1.19 | 1.06 | 0.90 | 0.81 |
Interest Cover(x) | 38.77 | 25.65 | 11.69 | 11.05 | 4.38 |
Total Debt/Mcap(x) | 0.03 | 0.04 | 0.08 | 0.09 | 0.12 |